Principia Biopharma raises uninhibited $50m

Apr 23, 2014 • Robert Lavine

The small molecule drug developer, which numbers SR One among its investors, has now secured $90m in overall capital.

US-based pharmaceutical company Principia Biopharma has secured $50m in a series B round backed by SR One, the corporate venturing subsidiary of healthcare company GlaxoSmithKline.

Founded in 2008, Principia develops small molecule inhibitor drugs to treat cancer and auto-immune diseases using technology originally licensed from University of California, San Francisco.

The round was led by private equity firm Sofinnova Ventures and also included all of Principia’s existing investors, including Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed Advisors, and Mission Bay…

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

FUNDING ROUND DATA

Which corporates are backing which startups? Search our corporate deal database.

CVC DIRECTORY

Find details about global CVC units in the CVC Directory

SPECIAL REPORT

Bumpy road: Self-driving cars make a cautious comeback

Events

GCV Institute: CVC Investment Programs

Jan 28 -
Jan 29, 2025
Online

Find out more All events

Events

Is now the right time to invest in autonomous driving?

Feb 19, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

Events

GCV Institute: CVC Investment Programs

Apr 8 -
Apr 10, 2025
Online

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

Apr 24 -
Jun 12, 2025
Online

Find out more All events

Events

GCV Symposium 2025

Jun 17 -
Jun 19, 2025
London (UK)

Find out more All events

About us

GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.